Molecular therapy in the microRNA era
- 26 December 2006
- journal article
- review article
- Published by Springer Nature in The Pharmacogenomics Journal
- Vol. 7 (5), 297-304
- https://doi.org/10.1038/sj.tpj.6500429
Abstract
MicroRNAs (miRNAs) consist of a growing class of non-coding RNAs (ncRNAs) that negatively regulate the expression of genes involved in development, differentiation, proliferation, apoptosis and other important cellular processes. miRNAs are usually 18–25 nt long and are each able to regulate several mRNAs by mechanisms such as incomplete base pairing and Post-Transcriptional Gene Silencing (PTGS). A growing number of reports have shown that aberrant miRNA expression is a common feature of human diseases including cancer, which has sparked interest in targeting these regulators of gene expression as a means of ameliorating these diseases. Here, we review important aspects of miRNA function in normal and pathological states and discuss new modalities of epigenetic intervention strategies that could be used to amend defects in miRNA/mRNA interactions.Keywords
This publication has 111 references indexed in Scilit:
- BIC and miR‐155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomasThe Journal of Pathology, 2005
- MicroRNA expression profiles classify human cancersNature, 2005
- c-Myc-regulated microRNAs modulate E2F1 expressionNature, 2005
- A microRNA polycistron as a potential human oncogeneNature, 2005
- Conserved Seed Pairing, Often Flanked by Adenosines, Indicates that Thousands of Human Genes are MicroRNA TargetsCell, 2005
- A pancreatic islet-specific microRNA regulates insulin secretionNature, 2004
- Processing of primary microRNAs by the Microprocessor complexNature, 2004
- Mechanisms of gene silencing by double-stranded RNANature, 2004
- The functions of animal microRNAsNature, 2004
- Non–coding RNA genes and the modern RNA worldNature Reviews Genetics, 2001